David A. Siegel Vertex Pharmaceuticals Inc Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 11,500 shares of VRTX stock, worth $4.99 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
11,500
Previous 900
1177.78%
Holding current value
$4.99 Million
Previous $400,000
1025.75%
% of portfolio
0.01%
Previous 0.0%
Shares
32 transactions
Others Institutions Holding VRTX
# of Institutions
1,787Shares Held
231MCall Options Held
1.83MPut Options Held
1.21M-
Capital World Investors Los Angeles, CA25.9MShares$11.2 Billion1.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA24.2MShares$10.5 Billion0.15% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.25 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA16.6MShares$7.18 Billion1.27% of portfolio
-
State Street Corp Boston, MA11.6MShares$5.04 Billion0.16% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $111B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...